United Therapeutics (UTHR) News Today → Get out of dollars—get into America’s new money instead (From Stansberry Research) (Ad) Free UTHR Stock Alerts $270.45 +2.73 (+1.02%) (As of 05/30/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 30 at 4:39 PM | marketbeat.comMartine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) Director Martine A. Rothblatt sold 3,600 shares of the company's stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $269.06, for a total transaction of $968,616.00. Following the completion of the transaction, the director now owns 130 shares of the company's stock, valued at approximately $34,977.80. The sale was disclosed in a filing with the SEC, which is available at this link.May 30 at 6:21 AM | marketbeat.comFranklin Resources Inc. Purchases 38,915 Shares of United Therapeutics Co. (NASDAQ:UTHR)Franklin Resources Inc. grew its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 355.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 49,851 shares of the biotechnology company's stoMay 29 at 11:13 AM | benzinga.comUnited Therapeutics Stock (NASDAQ:UTHR), Quotes and News SummaryMay 29 at 11:13 AM | finance.yahoo.comInvesting in United Therapeutics (NASDAQ:UTHR) five years ago would have delivered you a 213% gainMay 29 at 8:20 AM | marketbeat.comNomura Asset Management Co. Ltd. Acquires 7,971 Shares of United Therapeutics Co. (NASDAQ:UTHR)Nomura Asset Management Co. Ltd. lifted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 34.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 30,994 sharesMay 29 at 4:32 AM | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) Director Martine A. Rothblatt Sells 3,600 SharesMay 28 at 7:31 PM | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Director Sells $992,808.00 in StockUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) Director Martine A. Rothblatt sold 3,600 shares of the business's stock in a transaction on Thursday, May 23rd. The stock was sold at an average price of $275.78, for a total transaction of $992,808.00. Following the sale, the director now directly owns 130 shares in the company, valued at approximately $35,851.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.May 25, 2024 | marketbeat.comNorges Bank Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR)Norges Bank purchased a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 457,132 shares of the biotechnology company's stock, valued at approximately $100,5May 24, 2024 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) Director Martine A. Rothblatt Sells 1,468 SharesMay 24, 2024 | americanbankingnews.comStockNews.com Lowers United Therapeutics (NASDAQ:UTHR) to BuyMay 23, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Position Lessened by Weil Company Inc.Weil Company Inc. lessened its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 57.4% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 20,433 shares of the biotechnology company's stock after selling 27,587 shares dMay 23, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) Director Sells $404,947.80 in StockMay 22, 2024 | marketbeat.comQuest Partners LLC Takes Position in United Therapeutics Co. (NASDAQ:UTHR)Quest Partners LLC bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 3,500 shares of the biotechnology company's stock, valued at approximately $770,000. Several otherMay 22, 2024 | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Price Target Raised to $300.00 at JPMorgan Chase & Co.May 21, 2024 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) Price Target Raised to $300.00JPMorgan Chase & Co. increased their target price on shares of United Therapeutics from $280.00 to $300.00 and gave the company an "overweight" rating in a research report on Tuesday.May 21, 2024 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) Director Martine A. Rothblatt Sells 3,600 Shares of StockMay 21, 2024 | insidertrades.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) Director Sells 3,600 Shares of StockMay 20, 2024 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) Sets New 12-Month High at $275.42United Therapeutics (NASDAQ:UTHR) Hits New 12-Month High at $275.42May 20, 2024 | investorplace.com7 Biotech Stocks That Could Breathe New Life Into Your PortfolioMay 20, 2024 | marketbeat.comBI Asset Management Fondsmaeglerselskab A S Buys 13,988 Shares of United Therapeutics Co. (NASDAQ:UTHR)BI Asset Management Fondsmaeglerselskab A S increased its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 360.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,865 shares of the biotechnolMay 19, 2024 | marketbeat.comRobeco Institutional Asset Management B.V. Trims Stake in United Therapeutics Co. (NASDAQ:UTHR)Robeco Institutional Asset Management B.V. decreased its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 31.0% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 60,036 shares of the biotechnology company's stock after selling 27May 19, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Given Average Rating of "Moderate Buy" by BrokeragesShares of United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) have received a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and nine have given a buy ratMay 17, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by BNP Paribas Financial MarketsBNP Paribas Financial Markets increased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 90.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 55,481 shares of the biotechnology company's stocMay 16, 2024 | gurufocus.comInsider Sale: CFO and Treasurer James Edgemond Sells 40,160 Shares of United Therapeutics Corp ...May 16, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) Director Christopher Patusky Sells 1,310 SharesMay 15, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $955,728.00 in StockMay 15, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Has $70.15 Million Stake in United Therapeutics Co. (NASDAQ:UTHR)Charles Schwab Investment Management Inc. boosted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 2.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 319,03May 15, 2024 | seekingalpha.comMannKind Outperforms As Tyvaso DPI Captures Market ShareMay 15, 2024 | finance.yahoo.comQ1 2024 Liquidia Corp Earnings CallMay 13, 2024 | marketbeat.comInternational Assets Investment Management LLC Purchases 8,950 Shares of United Therapeutics Co. (NASDAQ:UTHR)International Assets Investment Management LLC boosted its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 13,769.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,015 shares ofMay 12, 2024 | marketbeat.comJump Financial LLC Has $8.94 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)Jump Financial LLC boosted its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 3,563.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 40,666 shares of the biotechnology company's stock after buying an additional 39,556 shaMay 11, 2024 | marketbeat.comAccess Investment Management LLC Takes $668,000 Position in United Therapeutics Co. (NASDAQ:UTHR)Access Investment Management LLC purchased a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 3,040 shares of the biotechnologyMay 11, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 3,600 SharesMay 10, 2024 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $951,192.00 in StockUnited Therapeutics Co. (NASDAQ:UTHR - Get Free Report) CEO Martine A. Rothblatt sold 3,600 shares of the company's stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $264.22, for a total transaction of $951,192.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company's stock, valued at approximately $34,348.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.May 9, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Olema Pharmaceuticals (OLMA), Arcus Biosciences (RCUS)May 8, 2024 | marketbeat.com4,880 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by Empirical Financial Services LLC d.b.a. Empirical Wealth ManagementEmpirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,880May 8, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $934,920.00 in StockMay 7, 2024 | finance.yahoo.comInsider Sale: Director Christopher Causey Sells Shares of United Therapeutics Corp (UTHR)May 7, 2024 | finance.yahoo.comInsider Sale: Director Judy Olian Sells Shares of United Therapeutics Corp (UTHR)May 7, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) Director Christopher Causey Sells 2,240 SharesMay 6, 2024 | investorplace.com3 Biotech Stocks to Double Your Money in the Next 24 MonthsMay 5, 2024 | marketbeat.comLSV Asset Management Lowers Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)LSV Asset Management lowered its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 1.5% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 377,368 shares of the biotechnology company's stock after selling 5,700 shaMay 4, 2024 | marketbeat.comLos Angeles Capital Management LLC Boosts Stake in United Therapeutics Co. (NASDAQ:UTHR)Los Angeles Capital Management LLC raised its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 43.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 73,405 shares of the biotechnoloMay 4, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $929,124.00 in StockMay 3, 2024 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) PT Raised to $240.00 at The Goldman Sachs GroupThe Goldman Sachs Group lifted their price target on shares of United Therapeutics from $218.00 to $240.00 and gave the company a "neutral" rating in a research note on Friday.May 3, 2024 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) Reaches New 1-Year High on Analyst UpgradeUnited Therapeutics (NASDAQ:UTHR) Sets New 1-Year High Following Analyst UpgradeMay 3, 2024 | marketbeat.comRussell Investments Group Ltd. Sells 33,986 Shares of United Therapeutics Co. (NASDAQ:UTHR)Russell Investments Group Ltd. decreased its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 29.8% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 79,931 shares of the biotechnology company's stock after selling 33,986 sharesMay 2, 2024 | markets.businessinsider.comBuy Rating on United Therapeutics: Strong Market Position and Growth Potential Despite New CompetitorsMay 2, 2024 | marketbeat.comSummit Global Investments Buys 12,095 Shares of United Therapeutics Co. (NASDAQ:UTHR)Summit Global Investments boosted its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 80.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 27,112 shares of the biotechnolMay 2, 2024 | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) Posts Quarterly Earnings Results, Beats Expectations By $0.54 EPSUnited Therapeutics (NASDAQ:UTHR - Get Free Report) released its quarterly earnings data on Wednesday. The biotechnology company reported $6.17 EPS for the quarter, topping the consensus estimate of $5.63 by $0.54. The firm had revenue of $677.70 million for the quarter, compared to the consensus estimate of $620.31 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The company's quarterly revenue was up 33.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $4.86 earnings per share. Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Email Address Urgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It! (Ad)The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"... CLICK HERE TO GET YOUR GUIDE NOW UTHR Media Mentions By Week UTHR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. UTHR News Sentiment▼1.190.82▲Average Medical News Sentiment UTHR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. UTHR Articles This Week▼147▲UTHR Articles Average Week Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BPMC News TEVA News BBIO News PRGO News BHVN News ARWR News BHC News BIIB News ALNY News BMRN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:UTHR) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersBiden Nomination CANCELED?The Freeport SocietyThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarGold Set to EXPLODE!Gold Safe ExchangeGet out of dollars—get into America’s new money insteadStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProA once-in-a-century profit opportunity?Digital Mavericks Media Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
